🚨 #Latebreaker at European Society of Cardiology #HeartFailure2025 🚨 Johann Bauersachs presented results from a LifeVest patient study showing high SCA treatment rates despite use of contemporary GDMT in 19000+ patient study.

📽️ Johann Bauersachs talks with Radcliffe Cardiology about the SCD-PROTECT study of 19,000+ LifeVest patients. The study demonstrated a high rate of SCA among LifeVest patients in the early phase of a new HFrEF diagnosis. "There was broad use of the fantastic four" said Bauersachs.

ZOLL LifeVest - The only WCD with RCT Data and 20+ years of clinical evidence you can trust. Explore how LifeVest innovations continue to deliver better outcomes: zollcms.com/44RsGmW

📢 ICYMI: LifeVest patient study SCD-PROTECT showed high SCA treatment rates despite use of contemporary GDMT. 📰 Learn more: zollcms.com/4332l44

❤️ “Wearing the HFMS, I have not had to go to the hospital to stay. I feel safe with it on.” 📹 WATCH: Marjorie, a heart failure patient, along with her prescriber, NP Julie Myers, discusses the benefits of ZOLL Heart Failure Management System in patient care. Learn more about

WATCH: NP Julie Myers, Meadville Medical Center, discusses HFMS and how it impacts her #heartfailure patients – like Marjorie, who shares her personal experience. With HFMS, NP Myers and her clinic staff are catching fluid increase in patients approximately a week before those

Next Week: Join the Bay Area EP Society Virtual Meeting -- Roderick Tung, MD, FACC, FHRS, presents ""New Insights into Human VT."" 📅 Mark your calendar now for next Tuesday, June 17, at 5:30–6:30 pm PT. 🔗 Join via Zoom: zollcms.com/448AWOx

Learn More: "New Insights into Human VT" Tonight at 5:30 pm PT: Join the Bay Area EP Society Virtual Meeting with Roderick Tung, MD, FACC, FHRS 🔗 Zoom: zollcms.com/448AWOx

When SCD is on the line, patients deserve a solution backed by rigorous evidence. ​ LifeVest is the most studied and proven WCD with 1M+ women and men protected.​ More: zollcms.com/3XiJKxK There is only one LifeVest.

🎤 “The HFMS non-invasive patch is one of the breakthroughs for heart failure management.” - Dr. Adam Hafeez Learn how ZOLL HFMS helps to reduce #HF readmissions and see the data from JACC-HF demonstrating a 38% reduction at 90 days: zollcms.com/4i074Zi

🎙️ ICYMI on EHRA Cardio Talk: “…In this early phase of a cardiomyopathy, early after diagnosis, this is a very vulnerable period and it has a high arrhythmic risk. So especially in this early phase, the patients can benefit from temporary protection” David Duncker and Marco

Results published in JACC-HF showed that ZOLL HFMS reduces relative risk of #HF readmission by 38% at 90 days. After implementing HFMS into his treatment plans, Dr. Adam Hafeez says, “We've been seeing a strong correlation with patients being enrolled in the HFMS program and

🎙️ ICYMI on Radcliffe Cardiology: “SCD-PROTECT showed that there is a high risk of SCA or SCD within the first month after diagnosis of reduced LVEF, despite the fact that there was broad use of the so-called fantastic four medication.” Johann Bauersachs discuss results of

When SCD is on the line, patients deserve innovations backed by real-world outcomes. 20+ years of continuous LifeVest innovation have delivered better patient experiences. Learn more: zollcms.com/3XiJKxK There is only one LifeVest.

📹 WATCH: Dr. Adam Hafeez discusses how remote monitoring with ZOLL Heart Failure Management System allows him to detect fluid changes before signs and symptoms appear and intervene, allowing for timely intervention. Learn more about HFMS: zollcms.com/4i074Zi

🚨 New late-breaker data (SCD-PROTECT): High SCA treatment rate despite contemporary GDMT in 19k+ consecutive LifeVest (NICM and MI/CAD) patients, confirming importance of SCD protection during initiation of GDMT. Learn more: zollcms.com/4lD1Sws

🕓 Coming up today at 10:30am ET 👇 Authors share a first look at results from SCD PROTECT, a new study evaluating SCD Risk in 19,500+ reduced EF patients during initiation of four-pillar GDMT.